浙江医药：XC2309注射液获得药物临床试验批准通知书

Core Viewpoint - Zhejiang Medicine has received approval from the National Medical Products Administration for the clinical trial of XC2309 injection, which is intended for treating gastrointestinal ulcer bleeding caused by various conditions [2] Group 1 - The clinical trial application for XC2309 injection has met the requirements for drug registration [2] - The approved indication for XC2309 injection is gastrointestinal ulcer bleeding [2]